Novo Nordisk logo displayed on the exterior of a company office building

MARKET TRENDS

22 Jan 2026

GLP-1 Drugs Get Cheaper and More Consumer-Friendly

Novo Nordisk and Eli Lilly roll out lower self-pay prices, reflecting a more consumer-oriented GLP-1 market shaped by policy, access, and ...

Pfizer corporate headquarters entrance with company logo

PARTNERSHIPS

20 Jan 2026

Pfizer Fast-Tracks Obesity Drug Push With $4.9B Metsera Deal

Pfizer’s $4.9B Metsera acquisition boosts its obesity pipeline, adding key drug candidates amid intensifying competition from Novo and pee...

Scientist analyzing peptide samples under a microscope during early-stage drug research

INSIGHTS

19 Jan 2026

AI, Cash, and a Clock Are Redefining Peptide Drug Development

Fresh funding and selective AI use are pushing peptide companies to prove progress earlier and with more discipline

Pre-filled GLP-1 injection pens used in obesity and metabolic disease treatment

REGULATORY

15 Jan 2026

FDA Reasserts Limits as GLP-1 Shortages Fade

As GLP-1 drug shortages ease, the FDA is enforcing long-standing compounding limits, reshaping risk and forcing peptide firms to adapt

Gloved hands holding blue and white capsules

PARTNERSHIPS

13 Jan 2026

Merck and PeptiDream Explore a New Angle on COVID-19

A PeptiDream and Merck partnership spotlights peptides as a flexible, early-stage antiviral option for COVID-19 and beyond

Eli Lilly signage on a pharmaceutical company building with a US flag above

INNOVATION

9 Jan 2026

The Race to Replace Needles With Pills Gets Smarter

AI-powered collaborations are speeding oral obesity and diabetes drugs, promising easier dosing and a faster path from discovery to market

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.